References

  1. Data on file. Available from CSL Behring as DOF PVG-002.
  2. Immune Deficiency Foundation (IDF). About primary immunodeficiencies. https://primaryimmune.org/about-primary-immunodeficiencies. Accessed September 15, 2017.
  3. Immune Deficiency Foundation (IDF). Specific diseases. https://primaryimmune.org/about-primary-immunodeficiencies/specific-disease-types. Accessed September 15, 2017.
  4. Immune Deficiency Foundation (IDF). Immunoglobulin therapy and other medical therapies for antibody deficiencies. https://primaryimmune.org/treatment-information/immunoglobulin-therapy. September 15, 2017.
  5. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532-538.
  6. Siegel J. IVIg medication safety: a stepwise guide to production selection and use. Pharm Pract News. Dec 2010.
  7. Siegel J. Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharm Pract News. Jan 2010.
  8. GBS/CIDP Foundation International. Recently diagnosed with CIDP. https://www.gbs-cidp.org/cidp/all-about-cidp/. Accessed September 15, 2017.
  9. US Dept of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Chronic inflammatory demyelinating polyneuropathy (CIDP). https://www.ninds.nih.gov/Disorders/All-Disorders/Chronic-Inflammatory-Demyelinating-Polyneuropathy-CIDP-Information-Page. Accessed September 15, 2017.
  10. US Dept of Health and Human Services. National Institute of Health. National Heart, Lung and Blood Institute. What is immune thrombocytopenia? https://www.nhlbi.nih.gov/health/health-topics/topics/itp/. Accessed September 15, 2017.
  11. Neunert C, Lim K, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;17(6):4190-4207.
  12. Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236.
  13. US Dept of Health and Human Services. National Institutes of Health. National Health, Lung, and Blood Institute. How is immune thrombocytopenia (ITP) treated? https://www.nhlbi.nih.gov/health/health-topics/topics/itp/treatment. Accessed September 15, 2017.
  14. National Institutes of Health: ClinicalTrials.gov. Safety and efficacy of intravenous immunoglobulin IgPro10 in patients with primary immunodeficiencies. https://clinicaltrials.gov/ct2/show/NCT00168025. Accessed September 15, 2017.
  15. Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137-144.
  16. Cramer M, Frei R, Sebald A, Maeder M. Stability over 36 months of new liquid 10% polyclonial immunoglobulin product (IgPro10. Privigen®) stabilized with L-proline. Vox Sang. 2009;96(3):219-225.
  17. Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biological. 2010;38(1):150-157.
  18. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5)734-745.
  19. Sun A, Teschner W, Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol. 2013;9(6):577-587.
  20. Simon HU, Späth PJ. IVIG mechanisms of action. Allergy. 2003;58(7):543-552.
  21. Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous polyclonal immunoglobulin in autoimmune diseases: clinical indications and mechanisms of action. Drug Discov Today Ther Strateg Autoimmun. 2009;6(1):5-11.
  22. Jacob S, Rajabally Y. Current proposed mechanism of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7(4):337-342.
  23. Imbach P, Lazarus AH, Kühne T. Intravenous immunoglobulin induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang. 2009;98(3):385-394.
  24. US Department of Health & Human Services, Center for Medicare & Medicaid Services. International Classification of Diseases, Tenth Revision, Clinical Modifications (ICD-10-CM). 2018 Codes Tables and Index. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2018/. Accessed September 15, 2017.
  25. American Medical Association. Medicine/hydration, therapeutic, prophylactic, diagnostic injections and infusions, and chemotherapy. In: American Medical Association, ed. CPT 2016. Chicago, IL: American Medical Association; 2016:650-651.
  26. US Department of Health and Human Services, Center for Medicare & Medicaid Services. HCPCS Release & Code Sets. https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Downloads/2017-Alpha-Numeric-Index.pdf. Accessed September 15, 2017.
  27. HIPAA Space Healthcare Procedure Coding System Codes Lookup S9338. https://www.hipaaspace.com/Medical_Billing/Coding/Healthcare_Common_Procedure_Coding_System/HCPCS_Codes_Lookup.aspx. Accessed September 15, 2017.
  28. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007; 27(5):497-502.
  29. Data on file. Available from CSL Behring as DOF PVG-003.
You are now leaving the current website.

Do you want to continue?

Please let us know if you are a:
Patient/Caregiver
Physician
Pharmacist
Other Healthcare Provider